



NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 5 Sep 2022 (#35)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-OD-22-195](#) New NIH "FORMS-H" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2023. This notice informs the applicant and recipient communities of changes to grant application forms and application guide instructions for due dates on or after January 25, 2023.

The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Plan Form
- PHS 398 Career Development Award Supplemental Form
- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form

For NIH, as part of the implementation of the 2023 NIH Data Management and Sharing Policy, a new "Other Plan(s)" attachment field has been added to the PHS 398 Research Plan Form and the PHS 398 Career Development Award Supplemental Form. Applicants must attach the required Data Management and Sharing Plan in this new field in FORMS-H applications. See [NOT-OD-21-013](#) and [NOT-OD-22-189](#) for more information. Note: Although the 2023 NIH

Data Management and Sharing Policy is not applicable to fellowship and institutional training grant applications, the new attachment field was added for potential future use with other plans.

[NOT-OD-22-189](#) Implementation Details for the NIH Data Management and Sharing Policy. The purpose of this notice is to inform the extramural research community of implementation details for the [NIH Policy for Data Management and Sharing \(DMS Policy\)](#) affecting grant and cooperative agreement applications submitted for receipt dates on or after January 25, 2023. The specific changes to competing grant and cooperative agreement application instructions clarified below will be implemented with application form packages identified with a Competition ID of “FORMS-H” and incorporated into the forthcoming FORMS-H application guides. Although the DMS Policy will apply also to Research and Development (R&D) contracts, NIH intramural research projects, and other funding agreements (e.g., Other Transactions), the forms changes and other implementation details provided in this Notice apply only to NIH extramural grant and cooperative agreement activities. Details applicable to R&D contracts will be incorporated into the appropriate Requests for Proposals, and details applicable to Other Transactions will be incorporated into the appropriate Research Opportunity Announcement.

[NOT-OD-22-190](#) Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022. This notice informs the community of NIH and AHRQ application due date adjustments to accommodate scheduled federal system downtime. Grants.gov has a planned production system outage from Friday, September 23, 2022 at 12:01 AM ET to Thursday, September 29, 2022 at 11:59 PM ET (see [Grants.gov calendar](#)). Grants.gov will use this time to migrate their services to the Cloud. In response, NIH and AHRQ due dates that fall on or between September 22 and September 30, 2022 will move to October 3, 2022.

3rd cohort of the African Postdoctoral Training Initiative (APTI) fellowships. APTI Training early career scientists to respond to Africa's challenges in global health. Nairobi, Kenya | Tuesday 16 August 2022. The African Academy of Sciences ([AAS](#)), in partnership with the U.S. National Institutes of Health ([NIH](#)) and the Bill & Melinda Gates Foundation ([BMGF](#)), announces a call for applications for the 3rd cohort of the African Postdoctoral Training Initiative ([APTI](#)) fellowships. APTI Fellows are trained and supported to become scientific leaders who can advocate for increased research and innovation projects in Africa. This is done through 4-year postdoctoral fellowships where APTI Fellows are placed in various laboratories of the NIH Institutes or Centers (i.e., Intramural Research Program) for 2 years before returning to their home institutions in Africa for another 2 years of research. Ultimately, APTI fellows are expected to be a part of an African regional and global web of collaborations connecting to their home institutions.

APTI fellowships are open to applications from fields of health research, with a focus on innovation aimed at the discovery and translation of transformative solutions to global health problems that are priorities for their home institutions and countries. Additionally, proposals should align with the focus areas of [BMGF](#), the [NIH](#), and the [AAS](#).

To be eligible, applicants must:

- Be citizens of an African country, currently employed in an academic, research, or government position in an African country
- Have a relevant doctoral degree (e.g., PhD, MD, MBBS) awarded no more than 7 years before the application submission deadline. Applicants whose doctoral degrees were awarded earlier may be considered on a case-by-case basis subject to justification (e.g., where one took a career break for family-related reasons or to seek asylum due to political instability). Such applicants should submit a request (with justification) for consideration
- Have less than 5 years of relevant research experience after the award of their doctoral degree, by their start date at the NIH. Brief periods of clinical work and/or teaching, that does not include research, may be allowable, but cannot exceed 2-3 years total.
- Be fluent in English – reading, writing, speaking, and listening.

Additional information:

- All applications and their supporting documents must be submitted in English. Supporting documents issued in a language other than English should be accompanied by their English translation.
- Applications must be submitted via the [AAS Grants Management system](#) (Ishango).

Submission of applications opens on **16 August 2022** and closes on **30 September 2022**, at 17:00 East African Time (GMT +3).

[NOT-OD-22-198](#) Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. [Changes for Genomic Data Sharing Plans](#). In an effort to reduce burden, NIH will no longer request separate sharing plans for research subject to both the [NIH Genomic Data Sharing Policy \(GDS Policy\)](#) and the [NIH](#)

[Policy for Data Management and Sharing \(DMS Policy\)](#). Applicants should provide a single Data Management and Sharing Plan that addresses considerations for both policies.

[NOT-CA-22-124](#) Pre-Application Webinar for [RFA-CA-22-019](#), Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional). The National Cancer Institute (NCI) will hold a pre-application webinar on Tuesday, September 20, 2022, from 11:00 AM - 12:00 PM (ET) for the Funding Opportunity Announcement (FOA) [RFA-CA-22-019](#) entitled "Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional)."

[NOT-DA-22-079](#) Notice of Availability of FAQ for [RFA-DA-23-011](#), "Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional)" All applicants are encouraged to review the FAQ prior to submitting their application.

[NOT-HG-22-033](#) National Human Genome Research Institute ([NHGRI](#)) implementation of NIH Policy on Acceptance for Review of Applications Requesting \$500,000 or More in Direct Costs in a Single Year. To ensure adequate time for review and consideration of requests, NHGRI strongly encourages the request be sent to a NHGRI Program Director (<https://www.genome.gov/research-funding/Division-and-Program-Directors>) at least **eight weeks** prior to the anticipated submission date.

[NOT-OD-22-205](#) The purpose of this notice is to further extend interim policy flexibilities regarding registration and results reporting for a subset of NIH-funded research whose primary purpose is basic experimental studies with humans (BESH) submitted in response to BESH Funding Opportunity Announcements (FOAs). These studies, referred to in [NOT-OD-18-212](#) as "prospective basic science studies involving human participants," meet both the [NIH definition of a "clinical trial"](#) and also the definition of basic research. NIH is extending the period of delayed enforcement for registration and results reporting, originally announced in [NOT-OD-18-212](#), through September 24, 2024. This delayed enforcement is only applicable to BESH studies submitted to funding opportunities designated as "basic experimental studies with humans." NIH continues to expect [Good Clinical Practice](#) (GCP) training in accordance with [NOT-OD-16-148](#) for all personnel involved in the conduct, oversight, or management of these BESH. NIH also continues to expect [posting of informed consent forms](#) in accordance with [NOT-OD-19-110](#) and as required by Section 46.116(h) of the Revised Common Rule for all BESH that obtain informed consent. Additionally, all such applications continue to require completion of the full [PHS Human Subjects and Clinical Trials Information form](#), and will be evaluated using the [clinical trial review criteria](#).

[NOT-AT-22-026](#) Request for Information (RFI): Investigators' interests in and barriers to research studies on the health effects of cannabis and its constituents. NIH is interested in gathering information about barriers, scientific interests, and needs associated with therapeutic cannabis or cannabinoid research from investigators conducting or interested in conducting research on cannabis, cannabinoid phytochemical constituents, and related compounds (synthetic compounds, terpenes etc.). Such information will be useful to NIH as it seeks to address the research infrastructure needs and identify areas of interest within this field. Interested individuals are requested to provide responses to any of the following topics, as well as any additional ideas.

Funding Opportunity Announcements (FOA)

1. Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-200](#)

Type:UG3/UH3

Application Due Date: Applications will be accepted on a rolling basis, beginning on September 3, 2022, through to September 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute on Drug Abuse (NIDA) seeks research for the discovery and development of medications to prevent and treat opioid use disorder (OUD) and/or psychostimulant (cocaine or methamphetamine) use disorder (PsUD) and overdose.

Budget: Application budgets are limited to \$3 million per year for direct costs. The maximum period of support is 5 years.

2. Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-202](#)

Type: U01

Application Due Date: will be accepted on a rolling basis, beginning on September 3, 2022, through to September 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute on Drug Abuse (NIDA) seeks to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.

Budget: NIH intends to fund an estimate of 5 awards per year. Application budgets are limited to \$5 million per year for direct costs and need to reflect the actual needs of the proposed project. The maximum period of support is 3 years.

3. Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-22-020](#)

Type: R01

Application Due Date: February 28, 2023 & October 26, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.

Budget: NIDDK intends to commit up to \$1 million to fund 1-3 awards in FY 2023 and up to \$1 million to fund 1-3 awards in FY 2024. The number of awards is contingent upon availability of funds and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$500,000 direct costs per year, exclusive of indirect costs on subcontracts, per year. Budgets are expected to reflect the actual needs of the proposed project. The scope of the project period should determine the project period. The maximum project period is 5 years.

4. BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-22-245](#)

Type: UM1

Application Due Date: June 28, 2023; February 15, 2024; October 17, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) is intended to support the creation of Centers for accelerated engineering and optimization of high-impact, molecular technologies to monitor and/or manipulate brain cell activity in experimental animals. The Centers will produce high-impact molecular probes such as, but not limited to, fluorescent protein indicators of neuronal state variables (e.g., intracellular calcium, membrane voltage, released neurotransmitters/neuromodulators, etc.), molecular integrators of neural activity, optogenetic, chemogenetic, sonogenetic, magnetogenetic actuators, and activity-dependent molecular switches. This FOA is part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN Initiative Armamentarium project, whose goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple species. In this FOA, technology optimization is sought for existing tools for brain cell monitoring or manipulation that are beyond the proof-of-concept stage and that can be delivered selectively as payloads to cell types using newly developed brain cell access reagents. Each Molecular Payloads Center is expected to integrate: (1) sufficiently scaled molecular engineering, (2) in vivo validation of improvements seen in engineering assays in intact brains of experimental animals, (3) benchmarking throughout the technology development against existing best-in-class tools, and (4) adaptation of tools into easily produced and applied formats for neuroscience users. Molecular Payloads Centers may also include optional demonstration experiments that establish groundbreaking capabilities of improved molecular tools in vivo. This FOA will foster close interaction between technologists and neurobiologists in a research consortium including tool developers funded by other Armamentarium FOAs for brain cell access reagents. The Armamentarium consortium will promote rigorous technology design, benchmarking, validation, and distribution of monitoring and/or manipulation tools and associated brain cell access reagents.

Budget: The issuing IC and partner components intend to commit an estimated total of \$13,000,000 per year to fund 5 to 9 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105